Hello, Guest!
  • Thursday, November 21, 2024
vaccine

Moderna Secures $472M BARDA Contract Modification for COVID-19 Vaccine Dev’t

Moderna has been awarded a potential $472M contract modification by the Biomedical Advanced Research and Development Authority to expand late-stage clinical trials of a messenger RNA-based vaccine candidate for the novel coronavirus.

BARDA’s additional funding commitment increases the potential value of the initial contract to $955M, the company said Sunday.

Under the modification, BARDA pledged funds to support Phase 3 tests of Moderna’s mRNA-1273 vaccine  including a study to be conducted with 30K participants.

The biotechnology firm will perform the participant-based trials with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases’ COVID-19 Prevention Trials Network.

“Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks,” said Moderna CEO Stephane Bancel.

The company aims to deliver 500M to 1B doses of the potential COVID-19 vaccine starting next year as part of the Trump administration’s Operation Warp Speed.

Video of the Day

Related Articles

Federal Government Awards $3.2B Vaccine Supply Contract to Pfizer Contract Awards

Federal Government Awards $3.2B Vaccine Supply Contract to Pfizer

The U.S. government is procuring up to 405 million COVID-19 vaccine doses from a partnership between Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) under a $3.2 billion firm-fixed-price contract. The Department of Health and Human Services said Wednesday it expects to receive the initial doses for both adult and pediatric use in the fall. “Vaccines

White House Backs Merck-J&J Vaccine Manufacturing Collaboration News

White House Backs Merck-J&J Vaccine Manufacturing Collaboration

The Biden administration is supporting collaboration between Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK) to produce more COVID-19 vaccine doses through the Defense Production Act. At the White House’s request, the Department of Health and Human Services has earmarked $105 million in initial funds to help Merck (NYSE: MRK) expand company facilities in

GlaxoSmithKline Lands $342M Army Vaccine Procurement Contract Contract Awards

GlaxoSmithKline Lands $342M Army Vaccine Procurement Contract

The U.S. Army has awarded pharmaceutical company GlaxoSmithKline a $342M contract to buy COVID-19 vaccines in mass quantities from multiple vendors. The service branch obligated the full contract amount at the time of award to support coronavirus response efforts at military sites within and outside the continental U.S., the Department of Defense said Thursday.